Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats

BACKGROUND: Abaloparatide is a parathyroid hormone receptor agonist that increases bone formation and reduces vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis. Animal studies indicate abaloparatide stimulates vertebral bone formation and enhances bony bridging and b...

Descripción completa

Detalles Bibliográficos
Autores principales: Arlt, Heike, Besschetnova, Tatiana, Ominsky, Michael S., Fredericks, Douglas C., Lanske, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984001/
https://www.ncbi.nlm.nih.gov/pubmed/33778406
http://dx.doi.org/10.1002/jsp2.1132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984001/
https://www.ncbi.nlm.nih.gov/pubmed/33778406
http://dx.doi.org/10.1002/jsp2.1132

Ejemplares similares